Kornimate/medical-research-clean huggingface dataset:
telemedicine evaluation for stem cell transplant patients

Conditions: Stem Cell Transplant Patients

Summary: telemedicine is a new area of health care where medical information is transferred through audiovisual media, such as a computer or a video camera, for the purpose of remote doctor's visits or examinations. this new area of health care is important to test because it can potentially provide real-time interactions between the patient and their health care team, including phone conversations, online communication, and/or home visits. many activities such as a history review or physical examination can be conducted virtually as compared to the traditional face-to face visits. the purpose of this study is to determine patient and health care team acceptance of a "virtual medical visit" as a substitute for a "face to face" visit for patients either preparing to receive a stem cell transplant or previously received a stem cell transplant.


Eligibility criteria:
inclusion criteria: * patients who underwent or are planning to undergo a hematopoietic progenitor cell transplantation for any disease. * participants must be able to read and understand english\* * age over 18 years of age since this pilot trial is only being performed in the adult bmt service non-english speaking patients have been excluded in this pilot study because we do not have the support for translation services at this time. additionally, the telemedicine instruments being used are not yet validated across all languages. potential patients will be identified according to their medical condition, type and complexity of stem cell transplant procedure performed, and distance from mskcc. the patients should: 1. minimal comorbidities, 2. be less than 75 years of age. these characteristics have been associated with good understanding and acceptance of telemedicine in other pilot trials. these characteristics will be assessed by the clinician. please note: patients on other therapeutic protocols will be eligible for this protocol as well. exclusion criteria: * medically unstable patient as deemed by the treating team.

Keywords: telemedicine virtual medical visit quality of life 11-022
ano-genital human papillomavirus (hpv) infection, precancerous lesions and genital warts among danish renal transplant recipients

Conditions: Anogenital Dysplasia

Summary: transplant-related malignancies have emerged as one of the important complications after organ transplantation. some studies have shown that transplant recipients have an increased risk of developing cancer, especially non-melanoma skin cancer. because of iatrogenic immunosuppression in these patients, there is an increasing focus on human papillomavirus (hpv) related cancers. the occurrence of hpv infection and ano-genital precancerous lesions and genital warts among danish renal transplant recipients (rtrs) is not known. relatively few controlled studies exist on the prevalence of ano-genital hpv infection, anal precancerous lesions and cervical precancerous lesions among rtrs. knowledge about hpv infection and hpv-related ano-genital precancerous lesions in renal transplant recipients, together with identification of factors that play a role for development of anal and cervical precancerous lesions, is important for the possibility of early detection and treatment to prevent progression to ano-genital cancers. cervical cytology has been used for decades to detect cervical intra-epithelial neoplasia (cin), whereas high-resolution anoscopy is a newer modality for the detection of anal intra-epithelial neoplasia (ain). international guidelines recommend annually screening against cervical cancer for female renal transplant recipients, but currently no recommendation exists on screening against anal cancer. aim: in a clinical study it is the aim to examine the prevalence of anal, penile, oral and cervical hpv infection as well as ano-genital dysplasia and ano-genital warts among 250 renal transplant recipients and an immunocompetent control group. furthermore to identify factors associated with the development of ain or cin such as hpv type, viral load, duration of immunosuppression, and lifestyle factors such as sexual habits, reproductive history, smoking and alcohol habits, history of genital warts and other infections, and socio-economic variables.


Eligibility criteria:
inclusion criteria: - case group: 1. renal transplant recipients men and women ≥ 18 years of age 2. ≥ 6 months posttransplantation 3. stabile immunosuppressive regime 4. no signs of acute rejection og the transplant control group: 1. health men and women ≥18years of age from the nevus clinic, laser clinic and non-melanoma skin cancer clinic, bispebjerg hospital, copenhagen exclusion criteria: * case group: 1. other known immunosuppression both case- og control group: 2. previous hpv vaccination 3. previous total hysterectomy 4. inflammatory bowel disease 5. hiv infection
the safety and efficacy of micro-energy ultrasound in the treatment of renal insufficiency after renal transplantation

Conditions: Renal Insufficiency; Renal Transplantation

Summary: the safety and efficacy of micro-energy ultrasound in the treatment of renal insufficiency after renal transplantation.

1. study purposes: to evaluate the safety and efficacy of micro-energy ultrasound in the treatment of renal dysfunction after renal transplantation by measuring serum creatinine, urine volume, urea nitrogen, and transplanted kidney ultrasound, etc. 2. study design: this is a randomized, double-blind, controlled, multicenter clinical trial. 3. study objects: patients with mild to moderate renal insufficiency after renal transplantation. 4. number of samples: 90 5. main study center: department of urology, the second affiliated hospital, school of medicine, zhejiang university, hangzhou, china. 6. treatments: test group: after installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed.patients were treated twice a week for 6 weeks. control group: the placebo was treated with an ultrasound therapy device and used in the same manner as the test group.

Eligibility criteria:
inclusion criteria: 1. more than half a year after renal transplantation, serum creatinine elevated over three times , patients with ineffective immunosuppressive drugs; 2. mild to moderate renal insufficiency (creatinine less than 442umol / l); 3. volunteer to participate in this clinical trial, comply with the requirements of this clinical trial and sign the informed consent form. exclusion criteria: 1. patients with severe renal insufficiency; 2. blood routine suggests acute and chronic blood system diseases; 3. b-ultrasound suggests transplanting hydronephrosis; 4. uncontrollable patients with diabetes, hypertension, and cardiovascular disease; 5. the investigator determined that it is not suitable for this clinical trial.
metabolomic profiling of eosinophilic esophagitis

Conditions: Eosinophilic Esophagitis

Summary: a prospective longitudinal, observational study of adolescent and adults that will identify novel metabolites associated with dysphagia in eosinophilic esophagitis (eoe).

in this study, the investigators seek to understand whether a metabolomic profile obtained from esophageal samples correlate with the symptom of dysphagia in adolescent and adults. the investigators hypothesize that intraluminal secreted metabolite(s) will change during episodes of dysphagia. the aim of the study will be to use a novel method of producing esophageal luminal samples, the esophageal string test, to capture esophageal metabolites when a patient is and is not experiencing dysphagia.

Eligibility criteria:
inclusion criteria: * subjects with eosinophilic esophagitis (eoe) and seen either at children's hospital colorado or university of colorado hospital for scheduled outpatient clinical assessment or upper gi endoscopy exclusion criteria: * acute food impaction at time of study * recent (within 2 months) use of systemic steroids * other known esophageal disease or esophageal injury (e.g. tracheoesophageal fistula, congenital stricture, caustic injury) * known other inflammatory bowel disease * inability to swallow the est
international registry of intra-arterial and endosaccular flow diverters (irf)

Conditions: Intracranial Aneurysm

Summary: this multicenter retrospective cohort study aims to evaluate and compare the technical performance, safety, and clinical outcomes of intracranial aneurysms treated with flow diverter stents and endosaccular flow disruptors.

flow diverters and endosaccular flow disruptors used for the treatment of intracranial aneurysms exhibit distinct procedural and clinical outcomes, with potential differences in device-specific parameters such as procedure time, radiation exposure, adjunct device requirements, and long-term angiographic success. since the completion of the pipeline embolization device (ped) for the intracranial treatment of aneurysms trial, the field of flow diversion has undergone continuous evolution with the development and approval of several devices. while these devices share a similar mechanism for aneurysm occlusion, their design and delivery systems can vary significantly. various studies have demonstrated a promising safety and efficacy profile; however, the available data for a direct comparison of the technical and clinical outcomes between these devices remains limited.

Eligibility criteria:
inclusion criteria: * adult patients (18 years of age or older) * underwent endovascular treatment with one of the following devices: a. flow diverter stents: i. pipeline flex (covidien, california, usa) ii. pipeline flex with shield technology (covidien) iii. surpass streamline (stryker neurovascular, california, usa) iv. surpass evolve (stryker) v. silk flow diverter (balt extrusion, montmorency, france) vi. flow-redirection intraluminal device (fred; microvention) vii. flow-redirection intraluminal device x (fred x; microvention) viii. p64 flow modulation device (phenox gmbh). b. endosaccular flow disruptors: i. woven endobridge (web; microvention) ii. luna/artisse system (medtronic) iii. medina embolic device (medtronic) iv. contour neurovascular system (cerus endovascular) v. neqstent coil assisted flow diverter (cerus endovascular) vi. pconus and pcanvas (phenox gmbh) vii. nexus aneurysm embolization system (endostream medical) viii. citadel™ embolization device (balt, usa) * complete medical records and follow-up data available exclusion criteria: * incomplete procedural or follow-up records * non-flow-diverter or non-flow-disruptor treatments (e.g., coiling-only cases) * aneurysms treated with investigational devices not listed within inclusion criteria

Keywords: endovascular registry flow diverter stents endosaccular flow disruptors flow diversion
japanese lead extraction registry

Conditions: Arrhythmia, Cardiac

Summary: japanese lead extraction (j-lex) registry is an observational nationwide registry, performed by japanese heart rhythm society, collaborated with the national cerebral and cardiovascular center. the acute success rate at discharge and the complications associated with transvenous lead extraction will be collected. j-lex registry will provide a reliable information on indications, methods, the success rate, complications and the prognosis at 30 days prognosis.

japanese lead extraction (j-lex) registry is a nationwide, multicenter, observational registry, performed by japanese heart rhythm society, collaborated with national cerebral and cardiovascular center. this study is a voluntary nationwide registry and data are collected prospectively using a research electronic data capture (redcap) system until 30 days after the lead extraction. the investigators will collect the data regarding patient's background and lead characteristic, medical history, details about lead extraction procedure, lead characteristics, and outcomes. the data were anonymized in a linkable manner at each study site before they were sent. based on the provided information, the annual incidence and predictive factors for outcome will be investigated by the event assessment committee.

Eligibility criteria:
inclusion criteria: * patients undergoing transvenous lead extraction in japan. exclusion criteria: * patients who receive open-chest surgical extraction alone. * patients who refused to consent.

Keywords: lead extraction pacemaker defibrillator complication redcap
lay user evaluation of the panbio™ hcv self-test

Conditions: HEPATITIS C (HCV)

Summary: this is a prospective, multi-centre study designed to evaluate the usability of the panbio™ hcv self test, when performed by untrained lay users in an observed study setting. the panbio™ hcv self test detects antibodies to hepatitis c virus (hcv). the study validation will be conducted in accordance with the world health organisation's technical guidance on hepatitis c rapid diagnostic tests for professional use and/or self-testing (tss-16).

hepatitis c is a liver disease caused by the hepatitis c virus. the virus can cause both acute and chronic disease, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness. globally, hepatitis c virus infects around 71 million people per year, resulting in 700,000 deaths. the who estimates that only 21% of individuals chronically infected with hcv are diagnosed, and the who hcv targets include increasing the diagnoses to 90% by 2030. who guidelines, published in 2021, strongly recommend offering self-testing for hcv as an additional approach to hcv testing services.

Eligibility criteria:
inclusion criteria: * participant is aged 14 or over * participant agrees to all aspects of the study and is able and willing to provide informed consent / assent with parental consent. exclusion criteria: * participant has already participated in this study on a previous occasion. * participant is aware of their hcv status * participant is deemed unfit for the study by the investigator. * participant has a condition deemed unfit by the investigator to safely perform or receive the test. * participant is a practising health-care professional or laboratory scientist / technician or has prior medical or laboratory training or experience * participant is currently enrolled in a study to evaluate an investigational drug or vaccine. * participant has a visual impairment that cannot be restored using glasses or contact lenses or is unable to read the instructions for use. * participant is unwilling or unable to provide informed consent. * participant has participated in the study "lay user evaluation of the panbio™ hcv self test: a prospective, multi-centre usability study to evaluate lay user labelling comprehension and test result interpretation".

Keywords: diagnostics rapid test untrained user hepatitis c lateral flow test
intraoperative use of clearedge device in breast conserving surgery

Conditions: Breast Cancer

Summary: multi center, pivotal prospective, randomized clinical trial the proposed randomized controlled study will evaluate the benefits of adding the clearedge imaging device to the standard of care (soc) of margins assessment in breast conserving surgeries. the study will assess whether there is an improvement in the detection of dcis or invasive cancer involved margins by measuring whether removal at the time of primary surgical treatment can reduce the need for repeat surgeries as compared to the soc, which does not use the device.

clearedge is a ce marked device already been used in several hospitals in the uk. it was used in a prospective single arm and 2 phases clinical study. it was demonstrated that surgeons successfully used the device to identify dcis or invasive cancer involved margins and that it can reduce the need for repeat surgeries by meeting the margins depth criteria to require repeat operations. european journal of oncology surgery. 2016; 42 (12): 1834-1840. in addition, the device was clinically evaluated by several hospitals.

Eligibility criteria:
inclusion criteria: 1. patients who are female (genotype) 2. patients aged above 18 years, inclusive 3. patients diagnosed with breast dcis or invasive cancer recommended for lumpectomy procedure 4. patients treated with neoadjuvant endocrine therapy may be enrolled exclusion criteria: 1. patients currently receiving chemotherapy 2. patients having prior ipsilateral surgical treatment for breast cancer 3. patients who have had radiation therapy for ipsilateral breast cancer or for other malignancy that includes breast tissue in the radiation field (e.g. hodgkin's lymphoma) 4. patients who have breast implants 5. patients who are pregnant and/or lactating 6. patients participating in other breast cancer studies involving surgical treatment to the breast in the past 6 months.

Keywords: breast cancer lumpectomy positive surgical margins
clinical trial of dipyridamole in schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder

Summary: this is a 6-week, randomized, double blind, parallel groups designed, olanzapine-controlled trial of oral dipyridamole in symptomatic patients with a (dsm iv) diagnosis of schizophrenia, schizoaffective or schizophreniform disorder. this pilot study aims to provide preliminary estimates of whether the effect sizes of dipyridamole on positive symptoms, negative symptoms, and cognitive deficits differ between schizophrenia patients treated with dipyridamole, and schizophrenia patients treated with olanzapine. a total of 30 subjects will be recruited locally.

since the demonstrated success of chlorpromazine in treating psychosis in the1950's, the pharmacotherapy of schizophrenia has focused mainly on drugs with antidopaminergic actions. these drugs have robust effects on reality distortion and disorganization symptom complexes, but minimal effect on cognitive impairment, negative symptoms, and functional outcome and quality of life measures. newer generation antipsychotic drugs have a similar profile of effects, with some advantages on the course of depression, hostility, suicide, hospital readmission rates and motor side effect measures. side effects such as weight gain, increase in cardiovascular stress and diabetes risk are associated with some new generation drugs. a new class of drugs is needed to address the inadequate effectiveness and the side-effect disadvantages of the currently available pharmacological agents for the treatment of schizophrenia. recently, new treatment strategies using nicotinergic drugs or agonists at the glycine modulatory site of the glutamatergic n-methyl-d-aspartate (nmda) receptor have been employed in clinical trials with mixed results. our proposal focuses on a clinically available adenosine agonist, dipyridamole, in a 6-week clinical trial. published data suggest effectiveness of dipyridamole in treating psychosis when added to haloperidol treatment. the effectiveness of dipyridamole alone in treating schizophrenia symptoms, although indirectly suggested by several lines of evidence, has not been tested.

Eligibility criteria:
inclusion criteria: * subjects between ages 18-65, both males and nonpregnant females (on birth control) diagnosis of schizophrenia, schizoaffective or schizophreniform disorder ability to give written informed consent total bprs score \> 27 psychosis subscale scores \> 7 exclusion criteria: * patients with coagulative disorders, bleeding diathesis or currently on anticoagulants, and patients with major medical illnesses (including hypertension, angina, and cardiovascular diseases) or an abnormal baseline ecg. patients with moderate to severe mental retardation. inability to sign informed consent. patients with a history of serious violence (e.g., suicide attempts, or assaultive behavior). patients on clozapine treatment within the 6 weeks leading to the double-blind phase. patients with a history of olanzapine non-response positive urine toxicology screen

Keywords: schizophrenia positive symptoms negative symptoms cognitive deficits
efficacy and safety study of np000888 in subjects with plaque and nail psoriasis

Conditions: Psoriasis

Summary: this study is to evaluate the efficacy and safety of topical application of np000888 ointment compared to vehicle in plaque and fingernail psoriasis subjects. duration of administration: 24 weeks


Eligibility criteria:
inclusion criteria: * subject with a clinical diagnosis of plaque psoriasis defined as an iga score at least 2 (mild) at screening and baseline visits * subject with a plaque psoriasis total body surface area (bsa) involvement of at least equal to 3% but less than 20% at screening and baseline visits * subject with a clinical diagnosis of fingernail psoriasis on at least 1 fingernail with a fingernail pga score from 2 (mild) to 4 (severe) at screening and baseline visits exclusion criteria: * subject with guttata, erythrodermic, exfoliative, inverse, pustular or palmo plantar, infected or ulcerated psoriasis or psoriasis involvement \>=20% bsa or an unstable form of psoriasis, defined as at least one flare in the previous month before screening visit * subject with chronic plaque psoriasis who are candidates for systemic therapy at screening and baseline visits * subject with clinical signs of psoriatic arthritis at screening and baseline visits * subject with a clinical diagnosis of fingernail psoriasis on at least 1 fingernail with a nail-pga score from 2 (mild) to 4 (severe) at screening and baseline visits.

Keywords: psoriasis